Zohreh Hoseinkhani
Overview
Explore the profile of Zohreh Hoseinkhani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samavati S, Yarani R, Kiani S, Hoseinkhani Z, Mehrabi M, Levitte S, et al.
J Inflamm (Lond)
. 2024 Jun;
21(1):20.
PMID: 38867277
Autoimmune diseases are caused by an imbalance in the immune system, producing autoantibodies that cause inflammation leading to tissue damage and organ dysfunction. Systemic Lupus Erythematosus (SLE) is one of...
2.
Jahani M, Yarani R, Rezazadeh D, Tahmasebi H, Hoseinkhani Z, Kiani S, et al.
Curr Cancer Drug Targets
. 2024 Apr;
25(3):257-269.
PMID: 38584530
Background: Doxorubicin (DOX) is a chemotherapy drug that is widely used in cancer therapy, especially in Triple-Negative Breast Cancer (TNBC) patients. Nevertheless, cytoprotective autophagy induction by DOX limits its cytotoxic...
3.
Norooznezhad A, Yarani R, Payandeh M, Hoseinkhani Z, Mahmoudi H, Kiani S, et al.
Heliyon
. 2023 Apr;
9(4):e15165.
PMID: 37095978
Introduction: Cancer is among the leading causes of death worldwide and affects a considerable number of individuals. Chemotherapy is one the most common treatment for this condition and hair loss...
4.
Moradi S, Jalili F, Hoseinkhani Z, Mansouri K
Adv Pharm Bull
. 2022 Nov;
12(4):686-699.
PMID: 36415645
Cardiovascular disease (CVD) is a major concern for health with high mortality rates around the world. CVD is often associated with partial or full occlusion of the blood vessel network....
5.
Pirsaheb M, Mohammadi S, Khodarahmi R, Hoseinkhani Z, Mansouri K, Payandeh M
J Fluoresc
. 2022 Jun;
32(5):1733-1741.
PMID: 35675001
In this research, DNA-modified carbon dots (CDs) were exploited to construct a fluorescence assay for breast cancer genes (BRCA1, a potential marker for cancer diagnosis) detection. For this purpose, water-soluble...
6.
Payandeh M, Habibi R, Norooznezhad A, Hoseinkhani Z, Mansouri F, Yarani R, et al.
Transfus Apher Sci
. 2022 May;
61(6):103454.
PMID: 35618640
Coronavirus disease 2019 (COVID-19) is still an emergency in many countries. Herein, we report treatment with human placental-derived mesenchymal stromal cells transfusion (hPD-MSCT) in a critically ill infant diagnosed with...
7.
Shackebaei D, Hesari M, Ramezani-Aliakbari S, Hoseinkhani Z, Ramezani-Aliakbari F
Hum Exp Toxicol
. 2022 Feb;
41:9603271211064532.
PMID: 35193428
Background: Gallic acid (GA) is a polyphenolic agent with interesting pharmacological impacts on the cardiovascular system. Objective: The present study purposed to study the protective effects of GA at 25...
8.
Mohammadi S, Salimi A, Hoseinkhani Z, Ghasemi F, Mansouri K
J Nanobiotechnology
. 2022 Feb;
20(1):73.
PMID: 35135571
Background: MicroRNAs have short sequences of 20 ~ 25-nucleotides which are similar among family members and play crucial regulatory roles in numerous biological processes, such as in cell development, metabolism,...
9.
Farhadi P, Yarani R, Valipour E, Kiani S, Hoseinkhani Z, Mansouri K
Biomed Pharmacother
. 2021 Dec;
146:112526.
PMID: 34906774
Metabolic reprogramming is a potential hallmark of tumor cells to support continuous proliferation. Metabolic heterogeneity in breast cancer patients has been highlighted as the driving cause of tumor progression and...
10.
Norooznezhad A, Yarani R, Payandeh M, Hoseinkhani Z, Kiani S, Taghizadeh E, et al.
J Cell Mol Med
. 2021 Dec;
26(2):588-592.
PMID: 34873830
No abstract available.